Macular Degeneration clinical trials at University of California Health
20 in progress, 8 open to eligible people
Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
open to eligible people ages 50 years and up
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
at UCSF
ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
open to eligible people ages 50 years and up
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2…
at UCLA
Goji vs. Fiber on Macular Degeneration
open to eligible people ages 50-95
The goal of this project is to conduct a clinical trial in 60 participants ranging from age 50-95 with small drusen who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 28g of goji berry intake or an…
at UC Davis
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
open to eligible people ages 50 years and up
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
at UC Davis
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
open to eligible people ages 50-89
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood…
at UC Irvine UCLA UCSF
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
open to eligible people ages 50-89
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel…
at UC Davis UCSD
ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
open to eligible people ages 18 years and up
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy…
at UCSF
Non Exudative AMD Imaged With SS-OCT- Extension
open to all eligible people
The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal…
at UCLA
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Sorry, not currently recruiting here
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
at UCLA
Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
at UCLA
Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Sorry, in progress, not accepting new patients
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study …
at UCLA UCSD
Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
“We hope to learn more about the safety and feasibility of using your own (autologous) stem cells extracted from your bone marrow.”
Sorry, in progress, not accepting new patients
This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.
at UC Davis
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Sorry, not currently recruiting here
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228…
at UCLA UCSD UCSF
Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
Sorry, in progress, not accepting new patients
The purpose of this open-label, multicenter study is to determine the long-term safety, pharmacokinetics and effects of ALK-001 (C20-D3-retinyl acetate) on the progression of Stargardt disease. This study is an extension of NCT02402660 and enrolls…
at UCLA
ALK-001 on Stargardt Disease
Sorry, accepting new patients by invitation only
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old.…
at UCLA
Post-Approval Study of the Implantable Miniature Telescope
Sorry, accepting new patients by invitation only
The objective of the PAS-01 study is to assess the safety of the intraocular as measured by the cumulative incidence of patients who within 5 years after implantation experience persistent vision-impairing corneal edema (corneal edema leading to…
at UC Davis
Strategies for Improving Linkage-to-Care After Eye Disease Screening
Sorry, not yet accepting patients
The goal of this randomized, parallel-group, controlled trial is to compare methods of enhancing linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease…
at UCSF
Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
Sorry, in progress, not accepting new patients
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
at UCLA
Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
Sorry, in progress, not accepting new patients
This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD…
at UC Davis
GARM II: A Study on the Genetics of Age-related Maculopathy
Sorry, in progress, not accepting new patients
The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of adults (49 to 65…
at UCLA
Our lead scientists for Macular Degeneration research studies include Susanna s Park, MD PhD Jacque Duncan SriniVas Sadda, MD Michael B Gorin, MD, PhD Pradeep S. Prasad, MD, MBA Jeremy Keenan, MD, MPH Glenn Yiu, MD, PhD Michael S. Ip, MD Robert M Hackman, PhD.
Last updated: